Xia, et al. “Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.” Cell Research, 2022. doi:10.1038/s41422-022-00617-x.
@article{Xia2022,
title = {Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant},
author = {Xia and Shuai and Chan and Fuk-Woo, Jasper and Wang and Lijue and Jiao and Fanke and Chik and Ka-Heng, Kenn and Chu and Hin and Lan and Qiaoshuai and Xu and Wei and Wang and Qian and Wang and Chao and Yuen and Kwok-Yung and Lu and Lu and Jiang and Shibo},
journal = {Cell Research},
year = {2022},
doi = {10.1038/s41422-022-00617-x},
url = {https://www.nature.com/articles/s41422-022-00617-x}
}